We are live on ! Find out more
IMTX icon

Immatics

85 hedge funds and large institutions have $656M invested in Immatics in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 24

3.69% more ownership

Funds ownership: 73.62%77.31% (+3.7%)

7% less funds holding

Funds holding: 9185 (-6)

18% less call options, than puts

Call options by funds: $4.26M | Put options by funds: $5.18M

24% less capital invested

Capital invested by funds: $866M → $656M (-$210M)

26% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 23

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
85
Holders Change
-6
Holders Change %
-6.59%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
17
Increased
34
Reduced
24
Closed
23
Calls
$4.26M
Puts
$5.18M
Net Calls
-$922K
Net Calls Change
+$7.14M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Investment Management
1
T. Rowe Price Investment Management
Maryland
$75.4M +$27.7M +3,225,141 +44%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$74.1M +$6.33M +736,709 +8%
PA
3
Perceptive Advisors
New York
$66.7M +$11.1M +1,297,297 +16%
BBA
4
Baker Bros. Advisors
New York
$51.7M +$7.15M +832,432 +13%
RI
5
RTW Investments
New York
$46.5M -$29.7M -3,459,460 -35%
VPC
6
Vestal Point Capital
New York
$44.6M +$21.7M +2,525,000 +67%
PBA
7
Paradigm Biocapital Advisors
New York
$38.5M +$13M +1,509,547 +39%
SCM
8
Suvretta Capital Management
New York
$36M +$43.5M +5,065,277 New
B
9
Braidwell
Connecticut
$24.9M +$16M +1,856,400 +113%
O
10
OrbiMed
New York
$22M +$9.29M +1,081,081 +54%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$17.5M -$8.88M -1,032,910 -30%
Morgan Stanley
12
Morgan Stanley
New York
$17.3M +$19.5M +2,274,475 +1,391%
Goldman Sachs
13
Goldman Sachs
New York
$16.9M +$19.5M +2,266,141 +1,983%
FLSM
14
Frazier Life Sciences Management
California
$15.3M +$6.82M +793,200 +59%
WP
15
Woodline Partners
California
$14.5M -$4.02M -467,738 -19%
RCM
16
RA Capital Management
Massachusetts
$12.4M
WA
17
Wasatch Advisors
Utah
$6.8M +$726K +84,541 +10%
SFM
18
Sphera Funds Management
Israel
$6.55M +$1.72M +200,000 +28%
UOTTAIMCU
19
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$4.96M
BlackRock
20
BlackRock
New York
$4.88M -$150K -17,474 -2%
6CM
21
683 Capital Management
New York
$4.62M -$430K -50,000 -7%
Artisan Partners
22
Artisan Partners
Wisconsin
$4.59M -$135K -15,710 -2%
NCM
23
Nantahala Capital Management
Connecticut
$4.12M -$402K -46,803 -7%
Schroder Investment Management Group
24
Schroder Investment Management Group
United Kingdom
$2.95M +$1.27M +147,547 +53%
ZP
25
Zimmer Partners
New York
$2.88M +$1.07M +125,000 +45%

IMTX Hedge Fund Activity: Q4 2024 in Review

85 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Immatics (IMTX) for Q4 2024, worth a combined $656M — down 24% from $866M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of IMTX and 17 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 34 added.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $43.5M. The largest seller was RTW Investments, cutting an estimated $29.7M.

  • 85 institutional investors held Immatics (IMTX) as of Q4 2024, down from 91 in Q3 2024.
  • Funds reported $656M of Immatics stock for Q4 2024, down 24% quarter-over-quarter.
  • 17 funds opened new Immatics positions in Q4 2024 and 23 closed out, a net change of -6 holders.
  • The largest Immatics buyer in Q4 2024 was Suvretta Capital Management, an estimated $43.5M added.
  • The largest Immatics seller in Q4 2024 was RTW Investments, an estimated $29.7M sold.

Based on aggregated 13F filings for Q4 2024.